| __timestamp | ImmunityBio, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 13774000 |
| Thursday, January 1, 2015 | 226206000 | 22479000 |
| Friday, January 1, 2016 | 94391000 | 27388000 |
| Sunday, January 1, 2017 | 53821000 | 35610000 |
| Monday, January 1, 2018 | 35463000 | 49007000 |
| Tuesday, January 1, 2019 | 46456000 | 61139000 |
| Wednesday, January 1, 2020 | 71318000 | 68836000 |
| Friday, January 1, 2021 | 135256000 | 97592000 |
| Saturday, January 1, 2022 | 102708000 | 106903000 |
| Sunday, January 1, 2023 | 129620000 | 120998000 |
Igniting the spark of knowledge
In the dynamic world of biotechnology, managing operational costs is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Vericel Corporation and ImmunityBio, Inc. over the past decade, from 2014 to 2023.
ImmunityBio, Inc. has seen a significant increase in SG&A expenses, peaking in 2015 with a staggering 2,262% rise compared to 2014. This trend reflects their aggressive expansion and investment in research and development. Meanwhile, Vericel Corporation has maintained a more consistent growth in expenses, with a notable 780% increase from 2014 to 2023, indicating a steady scaling of operations.
Understanding these financial strategies provides insights into how these companies balance innovation with operational efficiency, offering a glimpse into their future trajectories in the competitive biotech landscape.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
AbbVie Inc. vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: AstraZeneca PLC vs ImmunityBio, Inc. Trends and Insights
Breaking Down SG&A Expenses: argenx SE vs Vericel Corporation
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Cost Management Insights: SG&A Expenses for Viatris Inc. and ImmunityBio, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.